Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Janux Therapeutics, Inc. JANX
$12.76
-$0.25 (-1.93%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
546970398.00000000
-
week52high
23.64
-
week52low
9.40
-
Revenue
8612000
-
P/E TTM
-11
-
Beta
0.00000000
-
EPS
-1.47000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мар 2023 г. в 21:01
Описание компании
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 06 июл 2021 г. | |
| Cowen & Co. | Outperform | 06 июл 2021 г. | |
| B of A Securities | Buy | 06 июл 2021 г. | |
| William Blair | Outperform | 14 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Robinson Byron | A | 100000 | 100000 | 03 янв 2023 г. |
| Winter Charles M. | A | 100000 | 100000 | 03 янв 2023 г. |
| Godfrey Wayne | A | 110000 | 110000 | 03 янв 2023 г. |
| Reardon Tighe | A | 110000 | 110000 | 03 янв 2023 г. |
| Campbell David Alan | A | 310000 | 310000 | 03 янв 2023 г. |
| Meyer Andrew Hollman | A | 90000 | 90000 | 03 янв 2023 г. |
| Kung Winston | A | 9375 | 9375 | 21 сент 2022 г. |
| Kung Winston | A | 30000 | 30000 | 21 сент 2022 г. |
| Barrett Ronald W | A | 12500 | 12500 | 14 июн 2022 г. |
| McNulty Alana B. | A | 12500 | 12500 | 14 июн 2022 г. |
Новостная лента
Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Zacks Investment Research
10 янв 2023 г. в 13:32
Janux Therapeutics, Inc. (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Janux Therapeutics to Present at Upcoming Investor Conferences in November
Business Wire
22 ноя 2022 г. в 06:00
SAN DIEGO--( BUSINESS WIRE )--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings. Details of the presentations are as follows:
7 Short-Squeeze Stocks for Bold Contrarians to Consider
InvestorPlace
21 ноя 2022 г. в 12:22
Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's version of playing chicken.
Why Janux Therapeutics Shares Rose 33.1% This Week
The Motley Fool
22 окт 2022 г. в 10:01
The clinical-stage biotech company just began its first clinical trial.